|Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas|
RD Morin, S Assouline, M Alcaide, A Mohajeri, RL Johnston, L Chong, ...
Clinical cancer research 22 (9), 2290-2300, 2016
|Genetic inactivation of TRAF3 in canine and human B-cell lymphoma|
KR Bushell, Y Kim, FC Chan, S Ben-Neriah, A Jenks, M Alcaide, ...
Blood, The Journal of the American Society of Hematology 125 (6), 999-1005, 2015
|Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma|
SE Arthur, A Jiang, BM Grande, M Alcaide, R Cojocaru, CK Rushton, ...
Nature communications 9 (1), 1-14, 2018
|Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma|
M Alcaide, S Yu, K Bushell, D Fornika, JS Nielsen, BH Nelson, KK Mann, ...
Clinical chemistry 62 (9), 1238-1247, 2016
|FOXL2 402C> G mutation can be identified in the circulating tumor DNA of patients with adult-type granulosa cell tumor|
A Färkkilä, MK McConechy, W Yang, A Talhouk, Y Ng, A Lum, RD Morin, ...
The Journal of Molecular Diagnostics 19 (1), 126-136, 2017
|Disruption of the gut microbiota with antibiotics exacerbates acute vascular rejection|
K Rey, S Manku, W Enns, T Van Rossum, K Bushell, RD Morin, ...
Transplantation 102 (7), 1085, 2018
|Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits|
M Alcaide, S Yu, J Davidson, M Albuquerque, K Bushell, D Fornika, ...
Scientific reports 7 (1), 1-19, 2017
|A novel multiplex droplet digital PCR assay to identify and quantify KRAS mutations in clinical specimens|
M Alcaide, M Cheung, K Bushell, SE Arthur, HL Wong, J Karasinska, ...
The Journal of Molecular Diagnostics 21 (2), 214-227, 2019
|Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana …|
F Zaja, F Salvi, M Rossi, E Sabattini, A Evangelista, G Ciccone, ...
Leukemia & lymphoma 59 (12), 2904-2910, 2018
|Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma|
CK Rushton, SE Arthur, M Alcaide, M Cheung, A Jiang, KM Coyle, ...
Blood advances 4 (13), 2886-2898, 2020
|Recurrent patterns of clonal evolution in relapsed-refractory DLBCL following treatment with R-CHOP|
C Rushton, SE Arthur, M Alcaide, M Cheung, N Thomas, LK Hilton, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
|IDENTIFYING MUTATIONS ENRICHED IN RELAPSED‐REFRACTORY DLBCL TO DERIVE GENETIC FACTORS UNDERLYING TREATMENT RESISTANCE|
C Rushton, M Alcaide, M Cheung, N Thomas, S Arthur, N Michaud, ...
Hematological Oncology 37, 35-36, 2019
|Abstract IA42: Detecting and quantifying mutations associated with treatment resistance in aggressive lymphomas using ctDNA|
N Thomas, LK Hilton, N Michaud, K Bushell, R Rys, M Jain, L Shepherd, ...
Blood Cancer Discovery 1 (3 Supplement), IA42-IA42, 2020
|The use of circulating tumor DNA to study the genetic basis of treatment failure in rrDLBCL|
C Rushton, M Alcaide, J Davidson, M Cheung, K Bushell, S Yu, ...
EUROPEAN JOURNAL OF HUMAN GENETICS 27, 418-418, 2019
|FUNCTIONAL CHARACTERIZATION OF NFKBIZ 3′ UTR MUTATIONS IN DIFFUSE LARGE B‐CELL LYMPHOMA|
SE Arthur, A Mottok, R Cojocaru, A Jiang, BM Grande, M Alcaide, ...
Hematological Oncology 37, 74-75, 2019
|Identification of Recurrent Non-Coding Driver Mutations in Non-Hodgkin Lymphomas through Integrative Genomic Analysis of 777 Patients|
A Jiang, BM Grande, SE Arthur, M Alcaide, D Ennishi, S Jessa, ...
Blood 130 (Supplement 1), 36-36, 2017
|Functional Investigation of the Gene NFKBIZ and the Impact of 3'UTR Mutations in Diffuse Large B-Cell Lymphoma|
SE Arthur, A Mottok, M Alcaide, C Rushton, BM Grande, D Ennishi, ...
Blood 130 (Supplement 1), 1228-1228, 2017
|Genome-wide discovery of somatic coding and regulatory variants in Diffuse Large B-cell Lymphoma|
S Arthur, A Jiang, BM Grande, M Alcaide, A Mottok, D Ennishi, C Rushton, ...
BioRxiv, 225870, 2017
|P1. 02-011 Comparison of EGFR and KRAS Mutations in Archival Tissue and Circulating Tumor DNA: The Impact of Tumor Heterogeneity: Topic: Driver Genes in NSCLC, Resistance, and …|
Y Wang, C Ho, K Bushell, S Vandt, I Bosdet, L Swanson, J Laskin, S Sun, ...
Journal of Thoracic Oncology 12 (1), S493, 2017
|Genotype concordance between archival tumor DNA (atDNA) and circulating tumor DNA (ctDNA) in advanced solid malignancies: The Oncopanel Pilot study.|
HF Kennecke, K Bushell, CE McGahan, SA Vandt, JM Loree, I Bosdet, ...
Journal of Clinical Oncology 34 (15_suppl), 1582-1582, 2016